Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated MYC expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a recurrent feature of BPDCN. Although recent studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rethnam, Malini, Tan, Darren Qiancheng, Tan, Shi Hao, Li, Jia, Yokomori, Rui, Li, Ying, Yang, Henry, Sanda, Takaomi, Suda, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631685/
https://www.ncbi.nlm.nih.gov/pubmed/35482445
http://dx.doi.org/10.1182/bloodadvances.2021006306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631685/
https://www.ncbi.nlm.nih.gov/pubmed/35482445
http://dx.doi.org/10.1182/bloodadvances.2021006306

Ejemplares similares